Now Is The Time To Bet on Myriad Genetics, Inc. (MYGN)’s Stock

Tobin Bernard, President Crescendo BioScience, subtracted 11,712 shares of Myriad Genetics, Inc. (MYGN) from its portfolio at the rate of $40.00 per share valuing $468,480 on Aug 01. The insider left behind 146,040 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $23.38, with a 2nd Resistance Point sitting at $25.83. Meanwhile, this company’s stock has a 1st Support Level at $19.29 and a 2nd Support Level at $17.65. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Myriad Genetics, Inc. (MYGN) was $20.93. Myriad Genetics, Inc. (MYGN) stock has lost -$12.24, or -36.90%, in the past five days. In the last full month, these shares have lost -$7.99, or -27.63%. In the past three months, this stock’s price has fallen by -$24.31, or -53.74%. This year-to-date, Myriad Genetics, Inc. (MYGN) shares have lost -$8.14, or -28.00%.

Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Myriad Genetics, Inc. (MYGN) stock, 50% of short-term indicators suggest that these shares are a “ Hold .” Meanwhile, 100% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 100% of long-term indicators suggest that this stock is a “ Sell .”

With 74,381 K shares outstanding, this company currently has a market capitalization of $2,610,773K. Myriad Genetics, Inc. (MYGN) generates $851,100 K in annual sales, amounting to annual net income of $4,600 K. This stock has generated a 1-Year Total Return of -45.37%, a 3-Year Total Return of 103.01%, and a 5-year Total Return of 6.88%. This stock’s 5-Year Dividend Growth is 0.00%, with its most recent dividend valued at $1.750 per share on 06/15/09. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.

In the most recently-reported fiscal quarter, which ended in 09/19, Myriad Genetics, Inc. (MYGN) reported earnings of -$0.03 per share. Wall Street analysts, on average, were expecting the company to report earnings of $0.26 per share, representing a -0.29 difference and -111.54% surprise. In the previous quarter ending in 06/19, the reported earnings of $0.30 represented a -0.10 difference from the consensus estimate calling for $0.40 per share, which was a -25.00% surprise.

For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is $0.41 per share. This estimate came from a total of 3 Wall Street Analysts. Of those market experts, the high estimate was $0.46 and the low estimate was $0.38. In the year-ago quarter, Myriad Genetics, Inc. (MYGN) generated per-share earnings of $0.30. If the analysts are correct about the current quarter’s earnings, the growth will be +36.67%.

Turning our focus now to insider trading activity, there have been 9 purchases (447,500 shares in total) and 40 sale (181,264 shares in total) in the last 3 months. In the last 6 months, there have been 16 insider buys amounting to 644,500 shares and 49 insider sales amounting to 414,976 shares. In the past full year, 22 insider purchases were made (involving 700,660 shares) and 52 insider sell-offs equivalent to 420,835 shares.

Moving onto liquidity, Myriad Genetics, Inc. (MYGN) has a Current Ratio of 2.96, a Quick Ratio of 2.69 and a Cash Ratio of 1.16. Looking at this company’s capital structure, its Total Debt to Total Equity is 21.44, its Total Debt to Total Capital is 17.66, and its Total Debt to Total Assets is now 14.02. Looking even further ahead into the future, its Long-Term Debt to Equity is 3.22 and its Long-Term Debt to Total Capital is 21.44.